NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
– EMA submission expected in 2H25 by partner Menarini –
– PREVAIL Phase 3 CVOT remains on track –
-- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively --
Read more at globenewswire.com20.21
-0.82 (-3.9%)
NASDAQ:NAMSW (6/13/2025, 8:25:22 PM)
9.41
-0.66 (-6.55%)
Find more stocks in the Stock Screener
NAMS Latest News and Analysis
6 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
